期刊文献+

蛋白酶体抑制剂MG-132阻碍破骨细胞分化成熟的研究

Inhibitive effect of proteasome inhibitor MG-132 on osteoclast
原文传递
导出
摘要 目的探讨蛋白酶抑制剂MG-132对破骨细胞分化成熟过程的影响。方法分离、培养新生兔四肢长骨破骨细胞,实验分4组:对照组、MG-132 0.001 mmol/L培养组、0.01 mmol/L培养组及0.1 mmol/L培养组。于培养第2、5、8 d取细胞玻片、皮质骨片进行HE、甲苯胺蓝、抗酒石酸酸性磷酸酶(TRAP)染色,光镜下观察染色阳性细胞和骨片吸收陷窝,扫描电镜下观察吸收陷窝形态。结果(1)与对照组(第5天:46.8±3.4,第8天:34.6±4.1)比较,MG-132 0.001 mmol/L培养组、0.01 mmol/L培养组及0.1 mmol/L培养组破骨细胞计数在培养5 d后明显降低,分别为40.4±4.6(P〈0.05)、38.4±3.9(P〈0.05)、31.9±5.6(P〈0.01);(2)破骨细胞计数与蛋白酶抑制剂MG-132浓度呈负相关(r=-0.342,P〈0.01);(3)与对照组比较,MG-132 0.01 mmol/L培养组及0.1 mmol/L培养组骨片骨陷窝计数在培养第2、5、8天时,均明显减少(P〈0.05),0.001 mmol/L培养组与对照组比较差异无统计学意义。结论蛋白酶抑制剂MG-132可阻碍破骨细胞的分化成熟,抑制其蚀骨作用,并呈剂量依赖性。 Objective To observe the effect of proteasome inhibitor MG-132 on the differentiation and maturation of osteoclast.Methods The osteoclasts were isolated from the long bones of neonatal New Zealand S rabbits,and were cultured on the glass cover slips(10 mm×10 mm)and bone slices(10mm×10 mm×50μm).The plates of cultures were divided into four groups:control group,the group cocultured with 0.001 mmol/L MG-132,0.01 mmol/L MG-132 and 0.1 mmol/L MG-132.The glass cover slips and bone slices were stained by HE,toluidine blue and tartrate-resistant acid phosphatase(TRAP)at 2,5,8 days,and TRAP positive multi-nucleated cells and bone resorption lacunes were counted.Scanning electron microscopy was used to observe the pits of bone resorption.Osteoclasts were identified as multi-nucleated TRAP-positive cells.Results (1)Compare to the control group(5 d:46.8±3.4,8 d:34.6±4.1),the number of osteoclast was significantly decreased in MG-132 groups of 0.001 mmol/L(40.4±4.6,P〈0.05),0.01 mmol/L (38.4±3.9,P〈0.01)and 0.1 mmol/L(31.9±5.6,P〈0.01)at the fifth coculture day;(2) The number of osteoclast was negatively associated with the concentration of MG-132(r=-0.342,P〈0.01);(3)Since the second day,the number of bone resorption laeunes in group 0.01 mmol/L and group 0.1 mmol/L of MG-132 were significantly lower than those in control group(all P〈0.05). There was no significant difference in the number of bone resorption lacunes between group 0.001 mmol/L of MG-132 and control group(P〉0.05).Conclusions MG-132 could hinder the differentiation and maturation of osteoclast,and inhibit its bone resorption function in a dose dependent manner.
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2008年第1期53-56,共4页 Chinese Journal of Geriatrics
关键词 破骨细胞 蛋白酶抑制药 细胞凋亡 Osteoclasts Protease inhibitors Apoptosis
  • 相关文献

参考文献10

  • 1Zavrski I, Krebbel H, Wildemann B, et al. Proteasome inhibitors abrogate osteoelast differentiation and osteoelast function. Bioehem Biophys Res Commun, 2005,333 : 200-205.
  • 2高建军,金慰芳,王洪复.骨片吸收陷窝光镜计数法定量测定破骨细胞功能[J].上海医科大学学报,1998,25(1):71-73. 被引量:19
  • 3Ciechanover A. The ubiquitin- proteasome pathway:on protein deathand cell life. EMBO J, 1998, 17: 7151-7160.
  • 4Ling YH, Liebes L, Jiang JD, et al. Mechanisms of proteasome inhibitor PS- 341- induced G (2)-M- Phase arrest and apoptosis in human non- small cell lung cancer cell lines. Clin Cancer Res, 2003, 9: 1145- 1154.
  • 5Frankel A, Man S, Elliott P, et al. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res, 2000, 6: 3719-3728.
  • 6杨迪生,高翔,叶招明,陶惠民,李伟栩.蛋白酶体抑制剂MG132诱导骨肉瘤细胞凋亡及其对p27^(Kip1)蛋白表达的影响[J].中华骨科杂志,2005,25(10):613-617. 被引量:5
  • 7Meiners S, Laule M, Rother W, et al. Ubiquitinproteasome pathway as a new target for the prevention of restenosis. Circulatio, 2002,29:483-489.
  • 8Kakudo S, Miyazawa K, Kameda T, et al. Isolation of highly enriched rabbit osteoclasts from collagen gels a new assay system for bone-resorbing activity of mature osteoclasts. J Bone Miner Metab, 1996,14 : 129-136.
  • 9Thomas DM, Johnson SA, Sims NA, et al. Terminal osteoblast differentiation, mediated by runx2 and p27Kipl, is disrupted in osteosarcoma. J Cell Biol, 2004, 167: 925-934.
  • 10Weber KL. What's new in musculoskeletal oncology. J Bone Joint Surg, 2005, 87: 1400- 1410.

二级参考文献21

  • 1于明香,金慰芳,王洪复,关本博,林光义.破骨细胞体外培养与形态观察[J].上海医科大学学报,1996,23(1):52-54. 被引量:19
  • 2鄂征.组织培养和分子细胞学技术(第2版)[M].北京:北京出版社,1997.5.
  • 3高建军,中国骨质疏松症杂志,1997年,3卷,1期,79页
  • 4Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol, 2000, 18:4016-4027.
  • 5Marina N, Gebhardt M, Teot L, et al. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist, 2004, 9: 422-441.
  • 6Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J, 1998, 17: 7151-7160.
  • 7Ling YH, Liebes L, Jiang JD, et al. Mechanisms of proteasome inhibitor PS-341-induced G (2)-M-Phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res, 2003,9: 1145-1154.
  • 8Frankel A, Man S, Elliott P, et al. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res, 2000, 6: 3719-3728.
  • 9Lopes UG, Erhardt P, Yao R, et al. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem, 1997, 272: 12893-12896.
  • 10Herrmann JL, Briones F Jr, Brisbay S, et al. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene, 1998, 17: 2889-2899.

共引文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部